product name Anagrelide HCl
Description: Anagrelide HCl (also known as BL-4162A), the HCl salt of Anagrelide, is a drug used for the treatment of essential thrombocytosis. Anagrelide is a FDA-approved drug for the treatment of essential thrombocythemia. It is originally identified as a potential inhibitor of platelet aggregation. Anagrelide selectively affects thrombocytes while shows no significant effect on white blood cells, erythrocytes, or coagulation. Anagrelide is revealed to be available in 0.5mg capsules for oral administration.
References: Semin Thromb Hemost. 1997;23(4):379-83; N Engl J Med. 1988 May 19;318(20):1292-4.
292.55
Formula
C10H7Cl2N3O.HCl
CAS No.
58579-51-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 14 mg/mL (47.9 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
BL-4162A
other peoduct :
| In Vitro |
In vitro activity: Anagrelide is an oral imidazoquinazoline agent with an anti-cyclic AMP phosphodiesterase activity and inhibits platelet aggregation in both humans and animals. Anagrelide works by inhibiting the maturation of platelets from megakaryocytes. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Semin Thromb Hemost. 1997;23(4):379-83; N Engl J Med. 1988 May 19;318(20):1292-4. |
